PMID- 37925380
OWN - NLM
STAT- MEDLINE
DCOM- 20231221
LR  - 20240409
IS  - 1591-9528 (Electronic)
IS  - 1591-8890 (Print)
IS  - 1591-8890 (Linking)
VI  - 23
IP  - 8
DP  - 2023 Dec
TI  - Efficacy and safety of Orelabrutinib-based regimens in diffuse large B-cell 
      lymphoma: a single-center retrospective analysis.
PG  - 4609-4621
LID - 10.1007/s10238-023-01231-w [doi]
AB  - Currently, combining chemotherapy with Bruton tyrosine kinase inhibitors (BTKi) 
      has demonstrated significant effectiveness in treating patients with diffuse 
      large B-cell lymphoma. Orelabrutinib is a second-generation BTK inhibitor, and 
      presently, there have been few reports of Orelabrutinib being used to treat 
      DLBCL. We conducted a retrospective investigation to explore the safety and 
      efficacy of Orelabrutinib in combination with chemotherapy or immunotherapy. The 
      study comprised 19 patients with a median age of 61 years. The overall response 
      rate (ORR) was 89.5% with a complete response (CR) rate of 73.7% and a partial 
      response rate (PR) of 15.8%. The estimated 2-year overall survival (OS) and 
      progression-free survival (PFS) rates were 78.6% (95%CI, 59.8%-100%) and 72.2% 
      (95% CI, 52.4%-99.6%), respectively, with a median follow-up time of 11 months 
      (range 2-24). The most prevalent grade 3 or 4 adverse events (AEs), neutropenia 
      (52.6%), anemia (36.8%), thrombocytopenia (26.3%), febrile neutropenia (26.3%), 
      and lung infection (10.5%), were the most common. Our results reveal that 
      Orelabrutinib is an effective therapy for DLBCL patients. Furthermore, our first 
      investigation of the Orelabrutinib application lays a foundation for larger 
      retrospective studies.
CI  - (c) 2023. The Author(s).
FAU - Wei, Ruowen
AU  - Wei R
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
FAU - Wu, Yingying
AU  - Wu Y
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
FAU - Jiang, Shan
AU  - Jiang S
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
FAU - Zhang, Ao
AU  - Zhang A
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
FAU - Zhang, Lu
AU  - Zhang L
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
FAU - Liu, Ling
AU  - Liu L
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
FAU - Wang, Yadan
AU  - Wang Y
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
FAU - Zhang, Min
AU  - Zhang M
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
FAU - Mei, Heng
AU  - Mei H
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
FAU - Liu, Fang
AU  - Liu F
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
FAU - Xia, Linghui
AU  - Xia L
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
FAU - Cui, Guohui
AU  - Cui G
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
FAU - Fang, Jun
AU  - Fang J
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China. 
      junfangtyx@hust.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20231104
PL  - Italy
TA  - Clin Exp Med
JT  - Clinical and experimental medicine
JID - 100973405
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (orelabrutinib)
SB  - IM
MH  - Humans
MH  - Middle Aged
MH  - Rituximab
MH  - Retrospective Studies
MH  - Antibodies, Monoclonal, Murine-Derived
MH  - *Lymphoma, Large B-Cell, Diffuse/drug therapy/pathology
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
PMC - PMC10725366
OTO - NOTNLM
OT  - Diffuse large B-cell lymphoma
OT  - Orelabrutinib
COIS- There is no competing interest to report.
EDAT- 2023/11/05 06:41
MHDA- 2023/12/21 06:43
PMCR- 2023/11/04
CRDT- 2023/11/05 00:03
PHST- 2023/07/24 00:00 [received]
PHST- 2023/10/24 00:00 [accepted]
PHST- 2023/12/21 06:43 [medline]
PHST- 2023/11/05 06:41 [pubmed]
PHST- 2023/11/05 00:03 [entrez]
PHST- 2023/11/04 00:00 [pmc-release]
AID - 10.1007/s10238-023-01231-w [pii]
AID - 1231 [pii]
AID - 10.1007/s10238-023-01231-w [doi]
PST - ppublish
SO  - Clin Exp Med. 2023 Dec;23(8):4609-4621. doi: 10.1007/s10238-023-01231-w. Epub 
      2023 Nov 4.